BEIJING (Reuters) – China’s medical products regulator said on Saturday it has given conditional approval for Pfizer’s COVID-19 medicine Paxlovid to treat adults with mild to moderate disease who have high risk of progressing to a severe condition.
The National Medical Products Administration said further study on the drug needed to be conducted and submitted to the authority.
(Writing by William Mallard)
